This site is intended for
US Healthcare Professionals only.

Symdeko

ADDITIONAL RESPONSIVE MUTATIONS NOW APPROVED FOR SYMDEKO IN PATIENTS WITH CF AGED 6 YEARS AND OLDER1

Check Treatment Eligibility

Enter your patient’s mutations below to see if they are eligible for SYMDEKO.

SYMDEKO is indicated for the treatment of patients with cystic fibrosis (CF) age 6 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence.

Eligible

Please check to see if the mutation was entered correctly.

Results

Learn how to enter 2 or more mutations